Title:Dysregulated Long Non-coding RNAs in Myasthenia Gravis- A Mini-Review
Volume: 25
Issue: 1
Author(s): Liying Sun, Xuhui Ye, Linlin Wang, Junping Yu, Yan Wu, Yun Hua and Lihua Dai*
Affiliation:
- Intensive Care Unit, Shidong Hospital, Yangpu District, Shanghai, China
Keywords:
Long non-coding RNA, myasthenia gravis, pathophysiology, diagnostic biomarkers, therapeutic strategies, autoimmune disease.
Abstract: Myasthenia gravis (MG) is an acquired autoimmune disease that is
mediated by humoral immunity, supplemented by cellular immunity, along with
participation of the complement system. The pathogenesis of MG is complex; although
autoimmune dysfunction is clearly implicated, the specific mechanism remains unclear.
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with
lengths greater than 200 nucleotides, with increasing evidence of their rich biological
functions and high-level structure conservation. LncRNAs can directly interact with
proteins and microRNAs to regulate the expression of target genes at the transcription
and post-transcription levels. In recent years, emerging studies have suggested that
lncRNAs play roles in the differentiation of immune cells, secretion of immune factors,
and complement production in the human body. This suggests the involvement of
lncRNAs in the occurrence and progression of MG through various mechanisms. In
addition, the differentially expressed lncRNAs in peripheral biofluid may be used as a
biomarker to diagnose MG and evaluate its prognosis. Moreover, with the development
of lncRNA expression regulation technology, it is possible to regulate the differentiation
of immune cells and influence the immune response by regulating the expression of
lncRNAs, which will provide a potential therapeutic option for MG. Here, we review the
research progress on the role of lncRNAs in different pathophysiological events
contributing to MG, focusing on specific lncRNAs that may largely contribute to the
pathophysiology of MG, which could be used as potential diagnostic biomarkers and
therapeutic targets.
